ABSTRACT
Key Clinical Message: Medication-induced mood disorders following epidural steroid injections are possible therefore should be disclosed to the patient. Abstract: Medication-induced mood disorders have been rarely reported following epidural steroid injections (ESI). This case series presents three patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for substance/medication-induced mood disorder after an ESI. In considering a candidacy for ESI, the rare but significant, side effects of psychiatric side effects should be disclosed to patients.
ABSTRACT
Aim: This case series aimed to analyze the efficacy of a temporary peripheral nerve stimulation (PNS) device implanted for 60 days at 60 days post-explant for patients with non-surgical osteoarthritic knee pain. Patients & methods: 19 patients were selected for treatment with temporary PNS at an outpatient pain management clinic. Results: Patients demonstrated improvement in their knee pain from baseline post-temporary PNS explant (p = 0.973). Conclusion: Temporary PNS serves as a promising therapy for patients with limited options for therapy, necessitating further high-quality studies.
Temporary peripheral nerve stimulation (PNS) is a treatment for patients with knee swelling and pain who can't get surgery. The authors studied temporary PNS to see if the patient's knee pain improved. 19 patients were treated with temporary PNS. The study found the patients' knee pain improved after completing the treatment. More research is needed in the future to temporary PNS in knee pain patients.
Subject(s)
Electric Stimulation Therapy , Osteoarthritis, Knee , Transcutaneous Electric Nerve Stimulation , Humans , Treatment Outcome , Osteoarthritis, Knee/complications , Osteoarthritis, Knee/therapy , Follow-Up Studies , Pain , Peripheral NervesABSTRACT
A high prevalence of patients with spinal cord injury (SCI) suffer from chronic neuropathic pain. Unfortunately, the precise pathophysiological mechanisms underlying this phenomenon have yet to be clearly elucidated and targeted treatments are largely lacking. As an unfortunate consequence, neuropathic pain in the population with SCI is refractory to standard of care treatments and represents a significant contributor to morbidity and suffering. In recent years, advances from SCI-specific animal studies and translational models have furthered our understanding of the neuronal excitability, glial dysregulation, and chronic inflammation processes that facilitate neuropathic pain. These developments have served advantageously to facilitate exploration into the use of neuromodulation as a treatment modality. The use of intrathecal drug delivery (IDD), with novel pharmacotherapies, to treat chronic neuropathic pain has gained particular attention in both pre-clinical and clinical contexts. In this evidence-based narrative review, we provide a comprehensive exploration into the emerging evidence for the pathogenesis of neuropathic pain following SCI, the evidence basis for IDD as a therapeutic strategy, and novel pharmacologics across impactful animal and clinical studies.
